common (p < 0.05). The use of antidepressants (p < 0.001) and recurrence of encephalitis (p = 0.020) were higher in people with suicidality than in those without. Other characteristics were not significantly different in those who had suicidality and those who did not. Suicidality is a common and potentially lethal risk for people with anti-NMDAR encephalitis. Those presenting with psychiatric symptoms as the initial symptom and with insomnia, aggression, mania, depression and delusion should be carefully screened for suicidality. Closely monitoring people who have been treated with antidepressants is necessary.
Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder triggered by autoantibodies against the NR1 sub-unit of the NMDA receptor [1, 2] . More than 1000 cases have been reported since the first description in 2007 [2, 3] . Typical features include seizures, psychiatric symptoms, cognitive impairment, speech impairment, movement disorders, autonomic instability, central hypoventilation, and decreased consciousness [3] [4] [5] [6] . Psychiatric symptoms are often prominent and delusions, disorganised thoughts, hallucinations, agitation, aggression and insomnia have been reported [3] [4] [5] [6] [7] . Symptoms often resemble those of schizophrenia and this may result in misdiagnosis. Suicidality may be a complication of schizophrenia; in some series up to 40% of people with schizophrenia attempted suicide [8] [9] [10] . No studies, however, apart from some case series, appear to focus on suicidality amongst survivors of anti-NMDAR encephalitis [11] [12] [13] [14] [15] [16] [17] . In view of the similarity in presentation, we attempted to characterize suicidality in people who had had anti-NMDAR encephalitis, and summarize their clinical characteristics, risk factors and potential predictors.
Materials and methods

Patients
People who were admitted to the West China Hospital between June 2012 and February 2017 with a definitive diagnosis of anti-NMDAR encephalitis were enrolled into this retrospective observational study based on an existing registry. Diagnosis was based on clinical characteristics and confirmed by anti-NMDAR IgG antibody (Ab) screening in serum and cerebrospinal fluid (CSF). Serum and CSF samples of suspected cases were simultaneously obtained and sent to Peking Union Medical College Hospital, China or to Oumeng Biotechnology Corporation, Beijing, China, for testing. All samples were assessed by indirect immunofluorescence using EU 90 cells; the method was previously reported in detail [6, 18] . Concurrently, CSF and serum samples of those included were screened for other autoAbs, including Abs to contactin-associated protein-like 2, leucine-rich glioma inactivated 1, gamma aminobutyric acid beta receptor, and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and only individuals with negative results for all these other Abs were included in the study.
Standard protocol, approval and consent
The registry and this study were approved by the Ethical Committee of West China Hospital, Sichuan University, on human experimentation protocols (No. 20110818). Written informed consent was obtained from either the individual, their families or representatives.
Data extraction and management
People who developed suicidality were identified through reviewing the registry and evaluating inpatient and followup records. Demographics, clinical manifestations, results of auxiliary examinations, treatment strategies and outcomes were extracted. Clinical and psychiatric manifestations are provided in Table 3 . Mood was assessed by the Zung Depression Scale (ZDS) [19] and anxiety by the Zung Anxiety Scale (ZAS) [20] . Participants were deemed depressed if their ZDS score was ≥ 50, and anxious if their ZAS score was ≥ 45. EEG results were considered abnormal if clearcut epileptiform discharges or abnormal slow waves were recorded. For this study, only abnormalities likely to be encephalitis-induced were considered abnormal findings on MRI, according to clinicians' and radiologists' judgement; other abnormalities were not recorded. CSF results were considered abnormal if white blood cell counts (> 5/mm 3 ) or/and protein (> 0.45 g/L) were elevated. An anti-NMDAR antibody titer in CSF ≥ 1:100 was defined as strongly positive. Individuals were screened for an underlying tumor by tumor markers and MRI, ultrasound examination, and contrast-enhanced computed tomography of chest, abdomen, and pelvis. As for treatment, apart from first-line immunotherapies [intravenous immunoglobulin (IVIG) and methylprednisolone (MTP)], some also received drugs which have been related to possible suicidality, including levetiracetam (LEV) [21, 22] and antidepressants [23, 24] . All individuals were followed-up through telephone contact or outpatient clinic visits after the first month and every 3 months after treatment initiation. Outcomes were evaluated at the final follow-up using the modified Rankin Scale (mRS). Good outcome was defined as mRS scores 0-2 and poor outcome as mRS scores 3-6. Relapse of encephalitis was defined as new onset or worsening of symptoms occurring after an initial improvement or stabilization of at least 2 months [5] .
Definition of suicidality
Suicidality was classified according to the degree of severity. "Suicidal ideation" referred to expression of the thought of killing oneself without any practical attempt. "Attempted suicide" and "completed suicide" were regarded as suicidal behaviour where life-threatening behaviour occurred with the intention of jeopardizing life. Self-injurious behaviour with unknown intent was not included in suicidal behaviour [25] .
Statistical analysis
Statistical analyses were performed using SPSS version 21.0. Univariate analyses were performed to compare gender, age, initial symptoms, psychiatric symptoms, other symptomatic presentations, tumor findings, abnormal EEG results, abnormal MRI results, abnormal CSF results, strongly positive NMDAR-Ab in the CSF, positive NMDAR-Ab in the serum, treatment (immunotherapy and others), duration of follow-up, treatment outcomes, and rate of relapse between individuals with and without suicidality. Age and duration of follow-up were analyzed as continuous variables using the Wilcoxon test, while the remaining variables were analyzed as categorical variables (Fisher's exact test or the Chisquared test). A two-sided p value < 0.05 was considered to be statistically significant. 
Results
General clinical characteristics of individuals who presented with suicidality
During the period of interest 133 people were diagnosed with anti-NMDAR encephalitis. Seventeen (13%) presented suicidality after onset; 7 (5%) had suicidal ideation, 8 (6%) attempted suicide and 2 (1.5%) completed suicide. A further five people with self-injurious behavior were not included as intentions were unknown; one of them later died due to multiple organ dysfunction. The median interval between the initial symptoms of anti-NMDAR encephalitis and suicidality was 1 month (range 2 days-17 months); 10 of 17 had suicidality prior to admission, 3 during hospitalization, 2 after discharge, and 2 during relapse. The demographic and clinical characteristics of those with suicidality are presented in Table 1 . Median age was 27 years (range 16-78 years), and 13 (76%) were female. Fourteen individuals (82%) presented with psychiatric symptoms as the initial symptoms, while two presented with a seizure and one with speech dysfunction. Detailed information regarding psychiatric symptoms experienced by each individual is listed in Table 2 . Two (12%) were found to have neoplasia (one ovarian teratoma and one adrenal adenoma).
All 17 individuals with suicidality had positive NMDARAb in the CSF, with 6/17 being strongly positive; only 8/17 had positive serum antibodies. Brain MRI was abnormal in 3 individuals, including one who had a lesion near the left anterior horn of the lateral ventricle. The other two with abnormal MRIs had multifocal lesions; one had involvement of the left pons, cerebral peduncle, thalamus, callosum, frontal lobe, periventricular area, and bilateral internal capsules, while the other had involvement of the bilateral frontal and parietal lobes, periventricular triangle, and left anterior horn of the lateral ventricle. Although the MRIs of them showed a rather unusual pattern, both patients had a typical disease course and tested positive for NMDAR-Ab in CSF. Abnormal EEG results were present in 13 of 16 for whom results were available. Eight had abnormal CSF. The median follow-up duration was 13.5 months (range 1-48 months). Treatment outcomes of those with suicidality at the end of follow-up were assessed; 12 (71%) had a good outcome (mRS 0-2) and six (50%) of those made a full recovery (mRS 0). Five (29%) had a poor outcome (mRS 3-6) and, of those, three died. Of the 16 individuals with follow-up of 2 months or more, 5 (31%) had a recurrence.
Comparisons between those with and without suicidality
We compared the 17 individuals who had suicidality with the 116 without suicidality (Table 3) . Significantly more of those with suicidality had initial psychiatric symptoms (82 vs. 56%, Table 1 continued p = 0.039). Psychiatric symptoms in those with suicidality were also different from those without. The proportions with delusion, mania, insomnia, aggression, and depression were higher in those with suicidality than those without (univariate p < 0.05). There were no significant differences among other psychiatric symptoms (including disorganization, anxiety, agitation, hallucination and psychomotor inhibition). There were no significant differences between the two groups in gender, age, educational background, duration of follow-up, other clinical symptoms or auxiliary examination results. Seventeen individuals were treated with antidepressants, eight of those with suicidality and all six without took SSRIs; the other three with suicidality took SNRIs and 3 with suicidality took serotonin norepinephrine reuptake inhibitors (SNRIs). Those presenting with suicidality were more likely to be treated with an antidepressant than those without (65 vs. 5%, p < 0.001). There were no significant differences in the rate of being treated with LEV, IVIG, and MTP between the two groups. There were also no significant differences in treatment outcomes at final follow-up between the two groups, but those with suicidality had a higher rate of recurrence than those without suicidality (31 vs. 8%, p = 0.020).
Discussion
This study focusing on suicidality in people with anti-NMDAR encephalitis found that suicidality occurred in over 10% of individuals, with 1.5% eventually committing suicide. This is a higher suicide rate than suggested by the Chinese national disease surveillance system which provided annual figures between 7.69/100,000 and 7.72/100,000 for completed suicide rate in the general population around the time of the study [26] . This increase has also been reported in a small case series in which 3 of 12 people with anti-NMDAR encephalitis had suicidality (one with suicidal ideation and two with suicide attempts) [27] . One study of the NMDAR, NMDAR sub-unit mRNAs, and post-synaptic density protein 95 (PSD 95) in post-mortem brain tissue demonstrated that NMDAR sub-unit mRNAs levels and PSD 95 levels in people with suicidality were different from the control group [28] . Another study suggested that the levels of NMDAR antagonists and agonists were also related to suicidality [25] . Suicidality should, therefore, be seen not as rare, but as a common and potentially serious manifestation of anti-NMDAR encephalitis. The specific mechanism, however, warrants further study.
The demographic characteristics of those with suicidality suggest that it can affect individuals of different ages, and educational backgrounds. It can also present in different stages of encephalitis, from prior to admission, to after discharge and also during recurrence. One of those affected committed suicide 8 months post discharge after suffering from suspected depression for about 1 month. Followup prior to the onset of depression had noted full clinical recovery. It is possible that, as there was full recovery of consciousness, speech function, cognitive abilities, and other psychiatric symptoms, mood was overlooked and an evaluation of suicidality risk was not performed. Two further individuals had suicidal ideation or attempted suicide post discharge. Assessing the risk of suicidality is essential during telephone and outpatient clinic visits, even in those who appear to have had a good recovery.
We also analyzed clinical manifestations. Our cases presented with a variety of clinical symptoms (Table 1) . Those whose initial presentation included florid psychiatric symptoms were more likely to have suicidality than those who did not so present. Psychiatric symptoms were also different between the two groups on univariate analysis throughout (8) 0.020 c the course of the disease. These findings are consistent with previous studies of risk factors for suicidal behaviour in other mental disorders [29] [30] [31] [32] [33] . More attention should be paid to people with anti-NMDAR encephalitis with florid psychiatric symptoms, and assessment of the risk of suicidal behaviour should be made. Due to the small sample size of this study, we only performed a preliminary analysis; further multivariate analysis was not done to correct for the relationship between variables and identify independent predictors of suicidality. Further studies with larger samples are needed to identify suicidality predictors in people with anti-NMDAR encephalitis. Previous studies have shown that higher antibody titers were related to poorer outcomes [34, 35] . In this study, the preliminary analysis of those with strongly positive antibodies in the CSF showed no significant difference between those with and without suicidality (p = 0.257). The MRI results of individuals with suicidality may be normal, but may also show focal or multifocal lesions affecting the limbic system, frontal and parietal lobes, periventricular areas, internal capsule, callosum, pons, cerebral peduncles, and thalamus. A previous study showed that some lesions, such as smaller right parahippocampal cortex volume and superior temporal gyrus volume could be related to suicidality [36] . Due to small numbers and a relatively low rate of abnormal MRI in anti-NMDAR encephalitis, we could not ascertain relationships between suicidality and lesion location. No significant differences were found among MRI, EEG, and CSF results between the two groups.
People with suicidality were more likely to have taken antidepressants than those without. The US Food and Drug Administration requires a boxed warning of suicidal risk to be on the labels of all antidepressants, although data regarding this risk is still inconclusive [24, 25, 37, 38] and probably dependent of other variables such etiology, age and type of antidepressant [39, 40] . Due to the small number of people who took antidepressants we were unable to conduct further analysis on these variables. Individuals with suicidality also had a higher rate of having mood disorders which may explain the increase use of antidepressants. More attention has been paid to immunotherapies than to symptomatic treatment in people with anti-NMDAR encephalitis, and previous studies have rarely reported the use of antidepressants. We are, therefore, unable comment on whether antidepressants have an effect on suicidality in individuals with anti-NMDAR encephalitis. Close clinical monitoring of people who are treated with antidepressants is important. Further research is needed to identify the effect of antidepressants on people with anti-NMDAR encephalitis and whether there are differences among different age groups and different types of antidepressant.
Treatment outcomes at last follow-up were not significantly different between those with and without suicidality. Interestingly, two individuals had suicidality during a relapse but not during the first episode. Individuals with suicidality also had a higher rate of recurrence of encephalitis (31 vs. 8%, p = 0.020). We speculate, therefore, that there may be a relationship between relapse and suicidality. Previous reports suggest that symptomatology during relapse may be less severe than the first episode [5] . In those with recurrence, therefore, more attention should be paid to the increased risk of suicidality, rather than to the less severe symptoms. Studies with larger samples are needed to confirm these suggestions.
Our study has several limitations. First, mainly due to study design bias and the limitations inherent in uncontrolled retrospective research, we have not assessed suicidality consistently throughout the study period, particularly in the earlier stages. We have also not used a scale to estimate the severity of suicidality and this could have led to some recall bias although this may lead an underestimation of the suicidality. Second, due to the small sample of people with suicidality, multivariate analysis was not done and comparative results might be compromised. Third, as all individuals in the study were Chinese, our findings cannot be generalised to other settings, and further studies in more heterogeneous populations are required. Finally, the initial symptom was defined according to the clinician's expertise and the families' descriptions, which might cause interpretative bias, especially when the initial symptoms were not characteristic.
Conclusion
Our findings suggest that suicidality is a common, potentially lethal risk in people with anti-NMDAR encephalitis which should not be ignored by clinicians. People presenting with psychiatric symptoms such as insomnia, aggression, mania, depression, or delusions at the initial and subsequent presentations may be at particular risk and close monitoring is important, particularly of those taking antidepressants. Our study, however, has several limitations so our findings should be interpreted with caution. Further prospective studies with larger sample sizes and more precise classification of suicidality are urgently needed.
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